Potential Treatments for Food Allergy

Immunology and Allergy Clinics of North America

Volumn 35, Issue 1, 2015, Pages 77-100

  Albin, Stephanie ^a   Nowak Wegrzyn, Anna ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Desensitization; Food allergy; Food immunotherapy; Omalizumab; Tolerance

Indexed keywords

EGG PROTEIN; FLAGELLIN A; GSK 2245035; HAZELNUT EXTRACT; IMMUNOGLOBULIN E ANTIBODY; MEPOLIZUMAB; MILK PROTEIN; OMALIZUMAB; PEACH EXTRACT; PEANUT PROTEIN; PLACEBO; PLANT EXTRACT; PROBIOTIC AGENT; TALIZUMAB; TOLL LIKE RECEPTOR 7 AGONIST; TOLL LIKE RECEPTOR 9 AGONIST; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; VEGETABLE PROTEIN; ALLERGEN; ANTIALLERGIC AGENT; ANTIIDIOTYPIC ANTIBODY; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; TOLL LIKE RECEPTOR;

ALLERGIC ASTHMA; ALLERGIC DISEASE; ALLERGIC RHINITIS; ANTIBODY TITER; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); CROSS REACTION; DESENSITIZATION; DIET RESTRICTION; DIET SUPPLEMENTATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EGG ALLERGY; EOSINOPHILIC ESOPHAGITIS; EPICUTANEOUS IMMUNOTHERAPY; FOOD ALLERGY; HAZELNUT; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOTHERAPY; INFLAMMATORY BOWEL DISEASE; MAINTENANCE DRUG DOSE; META ANALYSIS (TOPIC); MILK ALLERGY; MULTICENTER STUDY (TOPIC); NONHUMAN; NUT ALLERGY; ORAL IMMUNOTHERAPY; OUTCOME ASSESSMENT; PEACH ALLERGY; PEANUT ALLERGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUBLINGUAL IMMUNOTHERAPY; THERAPY WITH HELMINTHS; TREATMENT DURATION; TREATMENT RESPONSE; AGONISTS; ANIMAL; DRUG EFFECTS; FOOD HYPERSENSITIVITY; HELMINTH; IMMUNOLOGY; PROCEDURES;

ALLERGENS; ANIMALS; ANTI-ALLERGIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; DESENSITIZATION, IMMUNOLOGIC; FOOD HYPERSENSITIVITY; HELMINTHS; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC FACTORS; PROBIOTICS; TOLL-LIKE RECEPTORS;

EID: 84927605032     PISSN: 08898561     EISSN: 15578607     Source Type: Journal    
DOI: 10.1016/j.iac.2014.09.011     Document Type: Review

References (108)

1. Boyce J.A., Assa'ad A., Burks A.W., et al. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. JAllergy Clin Immunol 2010, 126:S1-S58.
2. Burks A.W., Tang M., Sicherer S., et al. ICON: food allergy. JAllergy Clin Immunol 2012, 129:906-920.
3. Sicherer S.H., Sampson H.A. Food allergy: epidemiology, pathogenesis, diagnosis, and treatment. JAllergy Clin Immunol 2014, 133:291-307.e5.
4. Bock S.A., Munoz-Furlong A., Sampson H.A. Fatalities due to anaphylactic reactions to foods. JAllergy Clin Immunol 2001, 107:191-193.
5. Kulis M., Vickery B.P., Burks A.W. Pioneering immunotherapy for food allergy: clinical outcomes and modulation of the immune response. Immunol Res 2011, 49:216-226.
6. Oppenheimer J.J., Nelson H.S., Bock S.A., et al. Treatment of peanut allergy with rush immunotherapy. JAllergy Clin Immunol 1992, 90:256-262.
7. Nelson H.S., Lahr J., Rule R., et al. Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. JAllergy Clin Immunol 1997, 99:744-751.
8. Thyagarajan A., Burks A.W. Food allergy: present and future management. World Allergy Organ J 2009, 2:282-288.
9. Varshney P., Jones S.M., Scurlock A.M., et al. Arandomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. JAllergy Clin Immunol 2011, 127:654-660.
10. Syed A., Garcia M.A., Lyu S.C., et al. Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3). JAllergy Clin Immunol 2014, 133:500-510.e511.
11. Patriarca G., Nucera E., Pollastrini E., et al. Oral specific desensitization in food-allergic children. Dig Dis Sci 2007, 52:1662-1672.
12. Patriarca G., Nucera E., Roncallo C., et al. Oral desensitizing treatment in food allergy: clinical and immunological results. Aliment Pharmacol Ther 2003, 17:459-465.
13. Morisset M., Moneret-Vautrin D.A., Guenard L., et al. Oral desensitization in children with milk and egg allergies obtains recovery in a significant proportion of cases. A randomized study in 60 children with cow's milk allergy and 90 children with egg allergy. Eur Ann Allergy Clin Immunol 2007, 39:12-19.
14. Meglio P., Bartone E., Plantamura M., et al. Aprotocol for oral desensitization in children with IgE-mediated cow's milk allergy. Allergy 2004, 59:980-987.
15. Longo G., Barbi E., Berti I., et al. Specific oral tolerance induction in children with very severe cow's milk-induced reactions. JAllergy Clin Immunol 2008, 121:343-347.
16. Pajno G.B., Caminiti L., Crisafulli G., et al. Recent advances in immunotherapy: the active treatment of food allergy on the horizon. Expert Rev Clin Immunol 2013, 9:891-893.
17. Vickery B.P., Scurlock A.M., Kulis M., et al. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. JAllergy Clin Immunol 2014, 133:468-475.e6.
18. Factor J.M., Mendelson L., Lee J., et al. Effect of oral immunotherapy to peanut on food-specific quality of life. Ann Allergy Asthma Immunol 2012, 109:348-352.e342.
19. Carraro S., Frigo A.C., Perin M., et al. Impact of oral immunotherapy on quality of life in children with cow milk allergy: a pilot study. Int J Immunopathol Pharmacol 2012, 25:793-798.
20. Nowak-Wegrzyn A., Sampson H.A. Future therapies for food allergies. JAllergy Clin Immunol 2011, 127:558-573.
21. Blumchen K., Ulbricht H., Staden U., et al. Oral peanut immunotherapy in children with peanut anaphylaxis. JAllergy Clin Immunol 2010, 126:83-91.e81.
22. Anagnostou K., Islam S., King Y., et al. Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial. Lancet 2014, 383:1297-1304.
23. Nurmatov U., Venderbosch I., Devereux G., et al. Allergen-specific oral immunotherapy for peanut allergy. Cochrane Database Syst Rev 2012, (9). [Systematic reviews and meta-analyses], CD009014.
24. Sampson H.A. Peanut oral immunotherapy: is it ready for clinical practice?. JAllergy Clin Immunol Pract 2013, 1:15-21.
25. Staden U., Rolinck-Werninghaus C., Brewe F., et al. Specific oral tolerance induction in food allergy in children: efficacy and clinical patterns of reaction. Allergy 2007, 62:1261-1269.
26. Skripak J.M., Nash S.D., Rowley H., et al. Arandomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy. JAllergy Clin Immunol 2008, 122:1154-1160.
27. Narisety S.D., Skripak J.M., Steele P., et al. Open-label maintenance after milk oral immunotherapy for IgE-mediated cow's milk allergy. JAllergy Clin Immunol 2009, 124:610-612.
28. Keet C.A., Frischmeyer-Guerrerio P.A., Thyagarajan A., et al. The safety and efficacy of sublingual and oral immunotherapy for milk allergy. JAllergy Clin Immunol 2012, 129:448-455. 455.e1-5.
29. Keet C.A., Seopaul S., Knorr S., et al. Long-term follow-up of oral immunotherapy for cow's milk allergy. JAllergy Clin Immunol 2013, 132:737-739.e6.
30. Pajno G.B., Caminiti L., Salzano G., et al. Comparison between two maintenance feeding regimens after successful cow's milk oral desensitization. Pediatr Allergy Immunol 2013, 24:376-381.
31. Brozek J.L., Terracciano L., Hsu J., et al. Oral immunotherapy for IgE-mediated cow's milk allergy: a systematic review and meta-analysis. Clin Exp Allergy 2012, 42:363-374. [Systematic reviews and meta-analyses].
32. Buchanan A.D., Green T.D., Jones S.M., et al. Egg oral immunotherapy in nonanaphylactic children with egg allergy. JAllergy Clin Immunol 2007, 119:199-205.
33. Vickery B.P., Pons L., Kulis M., et al. Individualized IgE-based dosing of egg oral immunotherapy and the development of tolerance. Ann Allergy Asthma Immunol 2010, 105:444-450.
34. Burks A.W., Jones S.M., Wood R.A., et al. Oral immunotherapy for treatment of egg allergy in children. NEngl J Med 2012, 367:233-243.
35. Fisher H.R., du Toit G., Lack G. Specific oral tolerance induction in food allergic children: is oral desensitisation more effective than allergen avoidance?: a meta-analysis of published RCTs. Arch Dis Child 2011, 96:259-264. [Systematic reviews and meta-analyses].
36. Hofmann A.M., Scurlock A.M., Jones S.M., et al. Safety of a peanut oral immunotherapy protocol in children with peanut allergy. JAllergy Clin Immunol 2009, 124:286-291. 291.e1-6.
37. Varshney P., Steele P.H., Vickery B.P., et al. Adverse reactions during peanut oral immunotherapy home dosing. JAllergy Clin Immunol 2009, 124:1351-1352.
38. Sanchez-Garcia S., Rodriguez Del Rio P., Escudero C., et al. Possible eosinophilic esophagitis induced by milk oral immunotherapy. JAllergy Clin Immunol 2012, 129:1155-1157.
39. Ridolo E., De Angelis G.L., Dall'aglio P. Eosinophilic esophagitis after specific oral tolerance induction for egg protein. Ann Allergy Asthma Immunol 2011, 106:73-74.
40. Shankar T., Petrov A.A. Omalizumab and hypersensitivity reactions. Curr Opin Allergy Clin Immunol 2013, 13:19-24.
41. Nadeau K.C., Schneider L.C., Hoyte L., et al. Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy. JAllergy Clin Immunol 2011, 127:1622-1624.
42. Schneider L.C., Rachid R., LeBovidge J., et al. Apilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. JAllergy Clin Immunol 2013, 132:1368-1374.
43. Bégin P., Dominguez T., Wilson S.P., et al. Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab. Allergy Asthma Clin Immunol 2014, 10:7.
44. Chin S.J., Vickery B.P., Kulis M.D., et al. Sublingual versus oral immunotherapy for peanut-allergic children: a retrospective comparison. JAllergy Clin Immunol 2013, 132:476-478.e2.
45. de Boissieu D., Dupont C. Sublingual immunotherapy for cow's milk protein allergy: a preliminary report. Allergy 2006, 61:1238-1239.
46. Enrique E., Pineda F., Malek T., et al. Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. JAllergy Clin Immunol 2005, 116:1073-1079.
47. Enrique E., Malek T., Pineda F., et al. Sublingual immunotherapy for hazelnut food allergy: a follow-up study. Ann Allergy Asthma Immunol 2008, 100:283-284.
48. Fernandez-Rivas M., Garrido Fernandez S., Nadal J.A., et al. Randomized double-blind, placebo-controlled trial of sublingual immunotherapy with a Pru p 3 quantified peach extract. Allergy 2009, 64:876-883.
49. Kim E.H., Bird J.A., Kulis M., et al. Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. JAllergy Clin Immunol 2011, 127:640-646.e1.
50. Fleischer D.M., Burks A.W., Vickery B.P., et al. Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial. JAllergy Clin Immunol 2013, 131:119. 127.e1-7.
51. Dupont C., Kalach N., Soulaines P., et al. Cow's milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity. JAllergy Clin Immunol 2010, 125:1165-1167.
52. Dupont C., de Blay F., Guenard-Bilbault L., et al. Peanut epicutaneous immunotherapy (EPIT) in peanut-allergic children: 18 months treatment in the Arachild Study. JAllergy Clin Immunol 2014, 133:AB102.
53. Asero R. Effects of birch pollen-specific immunotherapy on apple allergy in birch pollen-hypersensitive patients. Clin Exp Allergy 1998, 28:1368-1373.
54. Asero R. How long does the effect of birch pollen injection SIT on apple allergy last?. Allergy 2003, 58:435-438.
55. Asero R. Effects of birch pollen SIT on apple allergy: a matter of dosage?. Allergy 2004, 59:1269-1271.
56. Bolhaar S.T., Tiemessen M.M., Zuidmeer L., et al. Efficacy of birch-pollen immunotherapy on cross-reactive food allergy confirmed by skin tests and double-blind food challenges. Clin Exp Allergy 2004, 34:761-769.
57. Bucher X., Pichler W.J., Dahinden C.A., et al. Effect of tree pollen specific, subcutaneous immunotherapy on the oral allergy syndrome to apple and hazelnut. Allergy 2004, 59:1272-1276.
58. Konstantinou G.N., Giavi S., Kalobatsou A., et al. Consumption of heat-treated egg by children allergic or sensitized to egg can affect the natural course of egg allergy: hypothesis-generating observations. JAllergy Clin Immunol 2008, 122:414-415.
59. Kim J.S., Nowak-Wegrzyn A., Sicherer S.H., et al. Dietary baked milk accelerates the resolution of cow's milk allergy in children. JAllergy Clin Immunol 2011, 128:125-131.e2.
60. Leonard S.A., Sampson H.A., Sicherer S.H., et al. Dietary baked egg accelerates resolution of egg allergy in children. JAllergy Clin Immunol 2012, 130:473-480.e1.
61. Huang F., Nowak-Wegrzyn A. Extensively heated milk and egg as oral immunotherapy. Curr Opin Allergy Clin Immunol 2012, 12:283-292.
62. Shreffler W.G., Wanich N., Moloney M., et al. Association of allergen-specific regulatory T cells with the onset of clinical tolerance to milk protein. JAllergy Clin Immunol 2009, 123:43-52.e7.
63. Ford L.S., Bloom K.A., Nowak-Wegrzyn A.H., et al. Basophil reactivity, wheal size, and immunoglobulin levels distinguish degrees of cow's milk tolerance. JAllergy Clin Immunol 2013, 131:180-186.e1-3.
64. Hong S.J., Michael J.G., Fehringer A., et al. Pepsin-digested peanut contains T-cell epitopes but no IgE epitopes. JAllergy Clin Immunol 1999, 104:473-478.
65. Prickett S.R., Voskamp A.L., Phan T., et al. Ara h 1 CD4+ T cell epitope-based peptides: candidates for a peanut allergy therapeutic. Clin Exp Allergy 2013, 43:684-697.
66. Zhou Y., Kawasaki H., Hsu S.C., et al. Oral tolerance to food-induced systemic anaphylaxis mediated by the C-type lectin SIGNR1. Nat Med 2010, 16:1128-1133.
67. Rupa P., Nakamura S., Katayama S., et al. Effects of ovalbumin glycoconjugates on alleviation of orally induced egg allergy in mice via dendritic-cell maturation and T-cell activation. Mol Nutr Food Res 2014, 58:405-417.
68. Pascal M., Konstantinou G.N., Masilamani M., et al. In silico prediction of Ara h 2 T cell epitopes in peanut-allergic children. Clin Exp Allergy 2013, 43:116-127.
69. Bannon G.A., Cockrell G., Connaughton C., et al. Engineering, characterization and invitro efficacy of the major peanut allergens for use in immunotherapy. Int Arch Allergy Immunol 2001, 124:70-72.
70. Li X.M., Srivastava K., Grishin A., et al. Persistent protective effect of heat-killed Escherichia coli producing "engineered," recombinant peanut proteins in a murine model of peanut allergy. JAllergy Clin Immunol 2003, 112:159-167.
71. Wood R.A., Sicherer S.H., Burks A.W., et al. Aphase 1 study of heat/phenol-killed, E.coli-encapsulated, recombinant modified peanut proteins Ara h 1, Ara h 2, and Ara h 3 (EMP-123) for the treatment of peanut allergy. Allergy 2013, 68:803-808.
72. Wang J. Treatment of food anaphylaxis with traditional Chinese herbal remedies: from mouse model to human clinical trials. Curr Opin Allergy Clin Immunol 2013, 13:386-391.
73. Srivastava K.D., Kattan J.D., Zou Z.M., et al. The Chinese herbal medicine formula FAHF-2 completely blocks anaphylactic reactions in a murine model of peanut allergy. JAllergy Clin Immunol 2005, 115:171-178.
74. Qu C., Srivastava K., Ko J., et al. Induction of tolerance after establishment of peanut allergy by the food allergy herbal formula-2 is associated with up-regulation of interferon-gamma. Clin Exp Allergy 2007, 37:846-855.
75. Wang J., Patil S.P., Yang N., et al. Safety, tolerability, and immunologic effects of a food allergy herbal formula in food allergic individuals: a randomized, double-blinded, placebo-controlled, dose escalation, phase 1 study. Ann Allergy Asthma Immunol 2010, 105:75-84.
76. Patil S.P., Wang J., Song Y., et al. Clinical safety of Food Allergy Herbal Formula-2 (FAHF-2) and inhibitory effect on basophils from patients with food allergy: extended phase I study. JAllergy Clin Immunol 2011, 128:1259-1265.e2.
77. Kalliomaki M., Kirjavainen P., Eerola E., et al. Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing. JAllergy Clin Immunol 2001, 107:129-134.
78. Vitaliti G., Pavone P., Guglielmo F., et al. The immunomodulatory effect of probiotics beyond atopy: an update. JAsthma 2014, 51:320-332. [Systematic reviews and meta-analyses].
79. Gore C., Custovic A., Tannock G.W., et al. Treatment and secondary prevention effects of the probiotics Lactobacillus paracasei or Bifidobacterium lactis on early infant eczema: randomized controlled trial with follow-up until age 3 years. Clin Exp Allergy 2012, 42:112-122.
80. Perrin Y., Nutten S., Audran R., et al. Comparison of two oral probiotic preparations in a randomized crossover trial highlights a potentially beneficial effect of Lactobacillus paracasei NCC2461 in patients with allergic rhinitis. Clin Transl Allergy 2014, 4:1.
81. Cabana M.D. No consistent evidence to date that prenatal or postnatal probiotic supplementation prevents childhood asthma and wheeze. Evid Based Med 2014, 19:144. [Systematic reviews and meta-analyses].
82. Silverberg J.I. Atopic dermatitis: an evidence-based treatment update. Am J Clin Dermatol 2014, 15:149-164. [Systematic reviews and meta-analyses].
83. Foolad N., Armstrong A.W. Prebiotics and probiotics: the prevention and reduction in severity of atopic dermatitis in children. Benef Microbes 2014, 5:151-160. [Systematic reviews and meta-analyses].
84. Schiavi E., Barletta B., Butteroni C., et al. Oral therapeutic administration of a probiotic mixture suppresses established Th2 responses and systemic anaphylaxis in a murine model of food allergy. Allergy 2011, 66:499-508.
85. Hol J., van Leer E.H., Elink Schuurman B.E., et al. The acquisition of tolerance toward cow's milk through probiotic supplementation: a randomized, controlled trial. JAllergy Clin Immunol 2008, 121:1448-1454.
86. Berni Canani R., Nocerino R., Terrin G., et al. Effect of Lactobacillus GG on tolerance acquisition in infants with cow's milk allergy: a randomized trial. JAllergy Clin Immunol 2012, 129:580-582. 582.e1-5.
87. Garg S.K., Croft A.M., Bager P. Helminth therapy (worms) for induction of remission in inflammatory bowel disease. Cochrane Database Syst Rev 2014, (1). [Systematic reviews and meta-analyses], CD009400.
88. Heylen M., Ruyssers N.E., Gielis E.M., et al. Of worms, mice and man: an overview of experimental and clinical helminth-based therapy for inflammatory bowel disease. Pharmacol Ther 2014, 143:153-167.
89. Amoah A.S., Boakye D.A., van Ree R., et al. Parasitic worms and allergies in childhood: insights from population studies 2008-2013. Pediatr Allergy Immunol 2014, 25:208-217.
90. Nagler-Anderson C. Helminth-induced immunoregulation of an allergic response to food. Chem Immunol Allergy 2006, 90:1-13.
91. Bager P., Arnved J., Ronborg S., et al. Trichuris suis ova therapy for allergic rhinitis: a randomized, double-blind, placebo-controlled clinical trial. JAllergy Clin Immunol 2010, 125:123-130.e1-3.
92. Jouvin M.H., Kinet J.P. Trichuris suis ova: testing a helminth-based therapy as an extension of the hygiene hypothesis. JAllergy Clin Immunol 2012, 130:3-10. [quiz: 11-2].
93. Schwaber J., Cohen E.P. Human x mouse somatic cell hybrid clone secreting immunoglobulins of both parental types. Nature 1973, 244:444-447.
94. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495-497.
95. Leung D.Y., Sampson H.A., Yunginger J.W., et al. Effect of anti-IgE therapy in patients with peanut allergy. NEngl J Med 2003, 348:986-993.
96. Sampson H.A., Leung D.Y., Burks A.W., et al. Aphase II, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. JAllergy Clin Immunol 2011, 127:1309-1310.e1.
97. Straumann A., Conus S., Grzonka P., et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut 2010, 59:21-30.
98. Assa'ad A.H., Gupta S.K., Collins M.H., et al. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology 2011, 141:1593-1604.
99. Otani I.M., Anilkumar A.A., Newbury R.O., et al. Anti-IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis. JAllergy Clin Immunol 2013, 131:1576-1582.
100. Aumeunier A., Grela F., Ramadan A., et al. Systemic Toll-like receptor stimulation suppresses experimental allergic asthma and autoimmune diabetes in NOD mice. PLoS One 2010, 5:e11484.
101. Duechs M.J., Hahn C., Benediktus E., et al. TLR agonist mediated suppression of allergic responses is associated with increased innate inflammation in the airways. Pulm Pharmacol Ther 2011, 24:203-214.
102. Beeh K.M., Kanniess F., Wagner F., et al. The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma. JAllergy Clin Immunol 2013, 131:866-874.
103. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2012 March 8-Identifier NCT01480271, An investigation of the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2245035 in healthy volunteers and allergic rhinitics. Available at: . Accessed April 28, 2014. http://clinicaltrials.gov/ct/show/NCT00287391?order=1.
104. Zhu F.G., Kandimalla E.R., Yu D., et al. Oral administration of a synthetic agonist of Toll-like receptor 9 potently modulates peanut-induced allergy in mice. JAllergy Clin Immunol 2007, 120:631-637.
105. Schulke S., Burggraf M., Waibler Z., et al. Afusion protein of flagellin and ovalbumin suppresses the TH2 response and prevents murine intestinal allergy. JAllergy Clin Immunol 2011, 128:1340-1348.e12.
106. Li X.M., Srivastava K., Huleatt J.W., et al. Engineered recombinant peanut protein and heat-killed Listeria monocytogenes coadministration protects against peanut-induced anaphylaxis in a murine model. JImmunol 2003, 170:3289-3295.
107. Frossard C.P., Steidler L., Eigenmann P.A. Oral administration of an IL-10-secreting Lactococcus lactis strain prevents food-induced IgE sensitization. JAllergy Clin Immunol 2007, 119:952-959.
108. Roy K., Mao H.Q., Huang S.K., et al. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med 1999, 5:387-391.